600 patients66,869 observations120 daysLIVE
← Patients

Patient P-01356

Synthetic patientNBL-101 · Day 116 · 45–54 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Improving
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
66%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 started — Baseline state S14
  2. Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
  3. Day 52 SC-12 recommended — Supportive Compound SC-12
  4. Day 53 Patient accepted — Started SC-12 in the companion
  5. Day 59 No meaningful change — Supportive Compound SC-12
  6. Day 60 GI-04 recommended — GI Support Protocol GI-04
  7. Day 61 Patient accepted — Started GI-04 in the companion
  8. Day 69 GI symptom burden −21% vs expected — GI Support Protocol GI-04
  9. Day 75 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days
  • Toxicity-11
  • Nutritional resilience-7
  • GI instability+4
  • Treatment adherence-4

What helped?

  • Supportive Compound SC-12Day 52
    Result: no meaningful change
  • GI Support Protocol GI-04Day 60
    Result: symptom burden −21%
LIFE OS recommendation
Dietary Support Protocol NP-02
59%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 66% showed improvement
  • median effect visible after 10 days
View similar patientsSimulateAdd to intervention cohortAll evidence

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
47.8/100
stable · +1.5 vs previous 14 d
Toxicity
Blood
37.5/100
improving · -2.2 vs previous 14 d
Sleep quality
Wearable
38.1/100
stable · -0.7 vs previous 14 d
Energy level
Daily log
2.8/10
worsening · -0.3 vs previous 14 d
Stress level
Daily log
4.7/10
stable · -0.0 vs previous 14 d
Steps
Wearable
2,806
improving · +251 vs previous 14 d
Adherence
Companion
48 %
stable · +0.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 34 from the failing basin, 53 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 78 similar · onset 3 d · confidence 71%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 71%
  • CR-01 Clinician Review
    100% improved among 8 similar · onset 5 d · confidence 71%
Would not help
  • SC-12 Supportive Compound
    already tried, no meaningful change
  • Keep fibre low
    GI +3.8 next day on high-intake days · n 19
  • Keep fat low
    GI +3.7 next day on high-intake days · n 13
  • Keep spicy low
    GI +2.8 next day on high-intake days · n 14
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Insoluble fibre
    +3.8detractor · 95%
  • Dietary fat load
    +3.7detractor · 95%
  • Spicy / capsaicin
    +2.8detractor · 75%
  • Histamine load
    +1.7no signal · 39%
  • Alcohol
    +0.8no signal · 15%
  • Simple carbohydrates
    +0.2no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity ↓60
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 48 and rising
    • WearableSleep 5.7 h, below personal baseline
  • Butyrate / short-chain fatty acid production ↓55
    • MicrobiomeButyrate capacity 24/100
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling ↑50
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 47
  • Autonomic recovery ↓40
    • Wearable2,806 steps/day
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 3 · butyrate capacity 24/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
55 ms
Sleep
5.9 h
Steps
2,783
Resting HR
70 bpm
Daily log: GI score 48, nutritional resilience 39, adherence 48.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Sort by similaritySort by interventionSort by outcomeSort by stateSort by response
PatientSimilarityBaselineInterventionOutcomeResponse today
P-0175023%S16——69
P-0169927%S04GI-04improved69
P-0150924%S17——68
P-0187523%S11——67
P-0181723%S14——67
P-0187724%S01CR-01improved67
P-0162923%S19——66
P-0171430%S14GI-04improved66
P-0185836%S14NP-02improved65
P-0131724%S19——65
P-0164324%S17——65
P-0141732%S14GI-04improved65